NSE - Delayed Quote INR

Lupin Limited (LUPIN.NS)

2,026.60
+21.80
+(1.09%)
At close: 3:29:59 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
221,921,100
221,921,100
196,563,400
162,699,800
161,927,900
Cost of Revenue
68,422,500
68,422,500
66,434,700
72,648,900
70,880,500
Gross Profit
153,498,600
153,498,600
130,128,700
90,050,900
91,047,400
Operating Expense
109,015,300
109,015,300
102,084,200
81,156,500
85,541,400
Operating Income
44,483,300
44,483,300
28,044,500
8,894,400
5,506,000
Net Non Operating Interest Income Expense
-2,948,700
-2,948,700
-3,116,100
-2,418,700
-1,099,600
Pretax Income
40,150,000
40,150,000
24,222,700
7,164,900
-13,722,100
Tax Provision
7,087,400
7,087,400
4,867,000
2,688,000
1,371,500
Net Income Common Stockholders
32,816,200
32,816,200
19,144,800
4,300,800
-15,280,400
Diluted NI Available to Com Stockholders
32,816,200
32,816,200
19,144,800
4,300,800
-15,280,400
Basic EPS
71.95
--
42.05
9.46
-33.65
Diluted EPS
71.69
--
41.87
9.41
-33.65
Basic Average Shares
456,097.29
--
455,286.56
454,692.96
454,042.89
Diluted Average Shares
457,751.43
--
457,243.85
456,946.99
455,240.30
Rent Expense Supplemental
--
--
696,900
702,700
680,800
Total Expenses
177,437,800
177,437,800
168,518,900
153,805,400
156,421,900
Net Income from Continuing & Discontinued Operation
32,816,200
32,816,200
19,144,800
4,300,800
-15,280,400
Normalized Income
35,616,598.10
35,616,598.10
20,752,933.95
4,393,963.31
-1,597,850
Interest Income
--
--
462,300
324,300
328,100
Interest Expense
2,948,700
2,948,700
3,116,100
2,402,100
1,072,600
Net Interest Income
-2,948,700
-2,948,700
-3,116,100
-2,418,700
-1,099,600
EBIT
43,098,700
43,098,700
27,338,800
9,567,000
-12,649,500
EBITDA
54,791,300
54,791,300
39,306,900
18,373,900
3,937,600
Reconciled Cost of Revenue
68,422,500
68,422,500
66,434,700
72,648,900
70,880,500
Reconciled Depreciation
11,692,600
11,692,600
11,968,100
8,806,900
16,587,100
Net Income from Continuing Operation Net Minority Interest
32,816,200
32,816,200
19,144,800
4,300,800
-15,280,400
Total Unusual Items Excluding Goodwill
-3,400,700
-3,400,700
-2,012,500
-149,100
-19,546,500
Total Unusual Items
-3,400,700
-3,400,700
-2,012,500
-149,100
-19,546,500
Normalized EBITDA
58,192,000
58,192,000
41,319,400
18,523,000
23,484,100
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-600,301.90
-600,301.90
-404,366.05
-55,936.69
-5,863,950
3/31/2022 - 9/10/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AUROPHARMA.NS Aurobindo Pharma Limited
1,161.00
-0.85%
 
SUNPHARMA.NS Sun Pharmaceutical Industries Limited
1,690.60
+0.11%
 
DRREDDY.NS Dr. Reddy's Laboratories Limited
1,351.10
+0.17%
 
GLENMARK.NS Glenmark Pharmaceuticals Limited
1,635.40
+1.23%
 
CIPLA.NS Cipla Limited
1,521.70
+0.72%
 
DIVISLAB.NS Divi's Laboratories Limited
6,719.00
+0.67%
 
TORNTPHARM.NS Torrent Pharmaceuticals Limited
3,205.80
-0.47%
 
LAURUSLABS.NS Laurus Labs Limited
676.45
+1.50%
 
ZYDUSLIFE.NS Zydus Lifesciences Limited
978.80
-0.31%
 
MANKIND.NS Mankind Pharma Limited
2,378.80
+0.10%